Get the Daily Brief

All action, no filler. BioBriefs delivers biotech’s 10 must-know updates, every morning.

Latest Biotech News

Novartis Deepens RNAi Therapeutics Portfolio with $160 Million Argo Biopharma Licensing Deal

September 06, 2025

Novartis expanded its cardiovascular RNA interference (RNAi) pipeline by entering a multi-asset licensing and option agreement with Argo Biopharma worth up to $5.2 billion. The upfront $160...

Atlas Venture Raises $400 Million Opportunity Fund to Bolster Portfolio Biotechs

September 06, 2025

Atlas Venture, a leading biotech venture capital firm, announced the close of a $400 million Opportunity Fund designed to support and advance its existing portfolio companies. This capital...

FDA Increases Transparency with Real-Time Release of Drug Rejection Letters

September 06, 2025

The FDA has taken a significant step towards regulatory transparency by committing to publish complete response letters (CRLs) immediately upon issuance to drug sponsors. This initiative follows...

Regulatory Advancements: FDA Outlines Pathways for Ultrarare Genetic Disease Therapies

September 06, 2025

The FDA unveiled the Rare Disease Evidence Principles (RDEP) program to expedite review of therapies for ultrarare genetic conditions affecting fewer than 1,000 patients in the U.S. The program...

Cancer Therapeutics Advances: Radiance Biopharma Signs $1.165B Deal for Novel Bispecific ADC

September 06, 2025

Radiance Biopharma secured global rights to a bispecific nanobody antibody-drug conjugate (ADC) targeting c-MET and EGFR, designed for solid tumor treatment, through a $1.165 billion agreement...

Notable Clinical Trial Results: BioNTech’s HER2 Antibody-Drug Conjugate Demonstrates Phase 3 Success

September 06, 2025

BioNTech and partner Duality Biologics revealed positive interim results from a phase III trial of their HER2-targeting antibody-drug conjugate (ADC) for HER2-positive breast cancer, achieving the...

Enveda Biosciences Secures $150 Million Series D to Accelerate Nature-Inspired Drug Discovery

September 06, 2025

Enveda Biosciences closed a $150 million Series D financing round, increasing its total funding to over $500 million, aimed at advancing its diverse pipeline of natural product-inspired...

Spaceflight Accelerates Aging of Human Hematopoietic Stem Cells, UC San Diego Finds

September 06, 2025

A landmark study by UC San Diego researchers revealed that human hematopoietic stem and progenitor cells (HSPCs) exhibit accelerated aging following exposure to spaceflight conditions. Using...

Novartis Commits $200 Million to Develop Arrowhead’s siRNA Therapy for Parkinson’s Disease

September 06, 2025

Novartis and Arrowhead Pharmaceuticals announced a landmark $200 million upfront licensing and collaboration deal focusing on Arrowhead’s preclinical small interfering RNA (siRNA) candidate...

Breakthrough in Mapping Human Proteins Crucial for SARS-CoV-2 Replication Unveiled

September 06, 2025

Scientists at Scripps Research have identified dozens of human host proteins critical to the replication and late stages of SARS-CoV-2 infection through an extensive genome-wide siRNA screening....

Novel Biomanufacturing Techniques Transform 3D Bioprinting with AI Integration

September 06, 2025

A collaborative team from UMC Utrecht and Utrecht University developed GRACE, an AI-enhanced volumetric bioprinting technology revolutionizing tissue engineering. This method integrates real-time...

Innovation in Cancer Immunotherapy: Oncolytic Viruses and CAR T Developments

September 05, 2025

Recent breakthroughs in cancer treatment highlight the integration of oncolytic viruses (OVs) with immunotherapy, offering new avenues by selectively targeting and lysing tumor cells while...

Targeting Molecular and Cellular Mechanisms in Cancer and Immunology

September 05, 2025

New insights into cancer progression and immune evasion have emerged, including discoveries of innate immune checkpoint inhibitors showing efficacy against solid tumors in preclinical models and...

FDA Transparency and Regulatory Advances in Drug Review Process

September 05, 2025

The FDA has committed to unprecedented transparency by publicly releasing complete response letters (CRLs) in real time upon issuance, alongside disclosures of previously unpublished CRLs related...

Biopharma Financing and Venture Capital Activity Signals Market Dynamics

September 05, 2025

The biotech investment landscape shows signs of resilience, with prominent venture capital firms like Atlas Venture raising substantial opportunity funds — $400 million in its latest round — to...

Neurodegeneration Insights: Genetic and Molecular Mechanisms Underpinning Brain Aging and Disease

September 05, 2025

Advanced single-cell and spatial transcriptomics studies have deepened understanding of brain aging and neurodegenerative conditions such as Alzheimer’s disease and Lewy body dementia. Noteworthy...

Gene Therapy and Cell Therapy Milestones in Rare Disease Treatment

September 05, 2025

Pioneering efforts in gene and cell therapies have yielded transformative outcomes for rare diseases, exemplified by the first FDA-approved islet cell transplant using Lantidra for Type 1 diabetes...

AI and Computational Advances Driving Precision Medicine and Biotech R&D

September 05, 2025

The integration of artificial intelligence and machine learning technologies is markedly accelerating discovery and development in biotech. Breakthroughs include the creation of AI-driven...

Major Deals and Partnerships Shaping Therapeutic Pipelines

September 05, 2025

Significant collaborations and licensing agreements are reshaping therapeutic landscapes, highlighted by Novartis’ $200 million collaboration with Arrowhead Pharmaceuticals to develop RNAi...

Bioprocessing and Manufacturing Innovations in Biopharma

September 05, 2025

Bioprocessing advancements are driving efficiency and scalability in drug manufacturing, particularly for complex modalities such as cell and gene therapies. Industry leaders emphasize the...